Back to Search
Start Over
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
- Source :
- Blood; November 2022, Vol. 140 Issue: Supplement 1 p400-402, 3p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 140
- Issue :
- Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs61223307
- Full Text :
- https://doi.org/10.1182/blood-2022-159009